Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal logo Université Clermont Auvergne & associés

Human Nutrition Unit

Zone de texte éditable et éditée et rééditée

Anne TOURNADRE, MD, PhD

Activities

Email : contact
Tel : +33 (0)4

Sarcopenia is a disease recognized by WHO on the international classification of ICD diseases (M62.8). Its prevalence increases with age and associated chronic diseases. Thus it affects about 10% of the over 65s, 50% of the over 80s. Its prevalence is also increased in chronic diseases, affecting 30% of patients with chronic rheumatic diseases. During chronic inflammatory rheumatic diseases (rheumatoid arthritis, spondyloarthritis, inflammatory myopathies), changes in body composition related to loss of mobility, inflammation, insulin resistance occur early. Muscle loss associated with increased adipose tissue is observed and defines the sarcopenic adiposity phenotype which contributes to cardiovascular and metabolic comorbidities and increased morbidity and mortality. In chronic inflammatory rheumatic diseases, the management of cardio-metabolic comorbidities (sarcopenic adiposity, metabolic syndrome, cardiovascular risk, osteoporosis) is therefore one of the major challenges. For this reason, the research activity aims to explore sarcopenia, metabolic disorders and associated comorbidities in chronic inflammatory joint and muscle diseases with reduced mobility such rheumatic diseases. Such knowledge is essential for the development of targeted, personalized and multimodal innovative therapeutic and preventive strategies based on biotherapies, nutrition and physical activity.

Research Activities

Characterization of the sarcopenia-associated phenotypes in chronic inflammatory rheumatic diseases (rheumatoid arthritis, spondyloarthritis, inflammatory myopathies): changes in muscle mass, body fat, and bone mass, metabolic disorders and associated cardiovascular comorbidities, energy expenditure taking into account the effect of treatments during a longitudinal follow-up.

Identification of mechanisms of sarcopenia and potential therapeutic targets during chronic inflammation: muscle lipotoxicity, impact of cytokine inhibitors and diet, identification of a biological signature in relation to muscle lipotoxicity and sarcopenia.

Development of diagnostic and monitoring tools: validation of sarcopenia biomarker on patients cohort, design predictive algorithms for a personalized prevention and care strategy.

Develop new therapeutic strategies combining targeted biotherapies, nutrition, physical activity.

Publications

  • Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, Frayssac T, Mathieu S, Malochet-Guinamand S, Soubrier M. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J  Cachexia Sarcopenia Muscle. 2017 Aug;8(4):639-646.
  • Tournadre A, Pereira B, Dubost JJ, Rincheval N, Rat AC, Combe B, Soubrier M. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. Clin Exp Rheumatol. 2017 Mar-Apr;35(2):296-302.
  • Nourisson C, Soubrier M, Mulliez A, Baillet A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Schaeverbeke T, Sibilia J, Vittecoq O, Ravaud P, Gottenberg JE, Mariette X, Tournadre A. Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry. RMD Open. 2017 Nov 1;3(2):e000515.
  • Marouen S, du Cailar G, Audo R, Lukas C, Vial G, Tournadre A, Barrat E, Ribstein J, Combe B, Morel J, Daien CI. Sodium excretion is higher in patients with rheumatoid arthritis than in matched controls. PLoS One. 2017 Oct 13;12(10):e0186157.
  • Malochet-Guinamand S, Pereira B, Tatar Z, Tournadre A, Moltó A, Dougados M, Soubrier M. Prevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures. BMC Musculoskelet Disord. 2017 Aug 22;18(1):357.

Curriculum Vitae

Current position : Professeur des universités-Praticien hospitalier, Department of rheumatology Hôpital G. Montpied, CHU de Clermont-Ferrand 63003 Clermont-Ferrand Cedex1
Medical Degree Course: Medical Doctor, University of  Clermont-Ferrand (2003) 
Scientific Degree Course:
- Habilitation à Diriger des Recherches / Accreditation to Supervise Research, University of Auvergne, Clermont-Ferrand  (2015)
- PhD, University of  Claude Bernard LYON I (2010)
- Research fellowship 2001/2002 : Clinical and Molecular Rheumatology Division Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (Pr A. Rosen et Dr K. Nagaraju)
        
Research Team :
Alimentation Santé MusculoSquelettique, Unité de Nutrition Humaine,  UMR 1019 INRA/Université d’Auvergne
Awards or grants:
- Programme Hospitalier de Recherche Clinique 2004 «Soluble IL-2 receptor: a biomarker for assessing myositis activity.»
- Programme Hospitalier de Recherche Clinique Interregional 2007 «Toll-Like Receptors (TLR) expression, Th1 and Th17 response, in inflammatory myopathiesdans les myopathies inflammatoires »
- Programme Hospitalier de Recherche Clinique Interregional 2013 « Eccentric Exercise and Cachexia in Rheumatoid Arthritis (EECRA) »
- Bourse Sirius UCB 2015-2016 « Lipidomic analysis of HDL in inflammatory rheumatic diseases: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis »
- Bourse Passerelle Pfizer 2017 «Evolution of total energy expenditure and its various components in active rheumatoid arthritis treated with anti-TNF agents and comparison with healthy subjects (EDEn-PRAc)»